These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11738619)

  • 1. CRHR1 Receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists.
    Hsin LW; Tian X; Webster EL; Coop A; Caldwell TM; Jacobson AE; Chrousos GP; Gold PW; Habib KE; Ayala A; Eckelman WC; Contoreggi C; Rice KC
    Bioorg Med Chem; 2002 Jan; 10(1):175-83. PubMed ID: 11738619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines: the development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor.
    Hsin LW; Webster EL; Chrousos GP; Gold PW; Eckelman WC; Contoreggi C; Rice KC
    Bioorg Med Chem Lett; 2000 Apr; 10(8):707-10. PubMed ID: 10782669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor.
    Aso K; Kobayashi K; Mochizuki M; Kanzaki N; Sako Y; Yano T
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2365-71. PubMed ID: 21414781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
    Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
    J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticotropin-releasing hormone receptor 1 coexists with endothelin-1 and modulates its mRNA expression and release in rat paraventricular nucleus during hypoxia.
    He JJ; Chen XQ; Wang L; Xu JF; Du JZ
    Neuroscience; 2008 Apr; 152(4):1006-14. PubMed ID: 18329812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [(76) Br]BMK-152, a nonpeptide analogue, with high affinity and low nonspecific binding for the corticotropin-releasing factor type 1 receptor.
    Jagoda EM; Lang L; McCullough K; Contoreggi C; Kim BM; Ma Y; Rice KC; Szajek LP; Eckelman WC; Kiesewetter DO
    Synapse; 2011 Sep; 65(9):910-8. PubMed ID: 21308801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis.
    Torres-Reverón A; Rivera-Lopez LL; Flores I; Appleyard CB
    PLoS One; 2018; 13(11):e0197698. PubMed ID: 30427841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation.
    Webster EL; Lewis DB; Torpy DJ; Zachman EK; Rice KC; Chrousos GP
    Endocrinology; 1996 Dec; 137(12):5747-50. PubMed ID: 8940412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
    Nielsen DM; Carey GJ; Gold LH
    Eur J Pharmacol; 2004 Sep; 499(1-2):135-46. PubMed ID: 15363960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of corticotropin-releasing hormone receptor antagonists on the ethanol-induced increase of dynorphin A1-8 release in the rat central amygdala.
    Lam MP; Gianoulakis C
    Alcohol; 2011 Nov; 45(7):621-30. PubMed ID: 21840158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of lasting dysregulation of neuroendocrine and HPA axis function following global cerebral ischemia in male rats and the effect of Antalarmin on plasma corticosterone level.
    de la Tremblaye PB; Raymond J; Milot MR; Merali Z; Plamondon H
    Horm Behav; 2014 Mar; 65(3):273-84. PubMed ID: 24444675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2.
    Jagoda E; Contoreggi C; Lee MJ; Kao CH; Szajek LP; Listwak S; Gold P; Chrousos G; Greiner E; Kim BM; Jacobson AE; Rice KC; Eckelman W
    J Med Chem; 2003 Aug; 46(17):3559-62. PubMed ID: 12904058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
    Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
    ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats.
    Briscoe RJ; Cabrera CL; Baird TJ; Rice KC; Woods JH
    Brain Res; 2000 Oct; 881(2):204-7. PubMed ID: 11036160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor.
    Martarello L; Kilts CD; Ely T; Owens MJ; Nemeroff CB; Camp M; Goodman MM
    Nucl Med Biol; 2001 Feb; 28(2):187-95. PubMed ID: 11295429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
    Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
    Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
    Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Aryl-2-anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists.
    Cocuzza AJ; Hobbs FW; Arnold CR; Chidester DR; Yarem JA; Culp S; Fitzgerald L; Gilligan PJ
    Bioorg Med Chem Lett; 1999 Apr; 9(7):1057-62. PubMed ID: 10230640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.